People with multiple sclerosis (MS) who have mild disability still experience several disease-related difficulties at work — challenges that can lead employees to shift to part-time or possibly quit their jobs — even after their condition is disclosed, a new study in Norway highlights. In particular, there are three…
News
A group of international experts has proposed a first-of-its-kind framework aimed at preventing multiple sclerosis (MS) from developing. Rather than focusing on a single cause, the framework outlines multiple opportunities to lower MS risk across a person’s life, from reducing childhood obesity and viral exposures to addressing smoking and…
Evogene and Unravel Biosciences are collaborating to develop a new class of therapies targeting myelin repair in multiple sclerosis (MS) and similar disorders. By combining two distinct artificial intelligence platforms, the companies hope to create the first treatment capable of…
Inflammatory gut bacteria that carry proteins structurally similar to myelin, a protective layer surrounding nerve fibers that is damaged in multiple sclerosis (MS), may trigger the development and progression of the disease, according to a new study done in mouse models. The findings may pave the way toward new…
Multiple sclerosis (MS) may follow two distinct biological paths that differ in how early and how quickly nerve damage develops, according to a new study. Using artificial intelligence (AI) to analyze brain MRI scans together with a blood test linked to nerve damage, researchers identified one MS pattern marked…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis that aims to protect the vision of people experiencing acute optic neuritis. This condition, which involves inflammation of the optic nerve, is a common and often debilitating symptom of…
The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help identify which patients are…
The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone…
The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service…
Women with multiple sclerosis (MS) who have children experience significantly longer waits before receiving a diagnosis than women without children, according to a new U.S. study. On average, each child was associated with an additional 1.28-year delay in diagnosis. The delay was even longer among women whose symptoms…
Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple…
Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic…
Throughout 2025, the team at Multiple Sclerosis News Today brought our readers the latest advances and updates in research related to multiple sclerosis (MS). Below are the top 10 most-read news stories we published this year. We look forward to continuing to serve the MS community in 2026 and…
After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed again…
Disability progression in relapsing forms of multiple sclerosis (MS) tends to follow one of four distinct patterns, according to long-term data from more than 5,000 people with relapsing-onset MS followed in an Italian registry. The study specifically found that disability progression could generally be categorized into four patterns: minimal-worsening,…
Immutep’s experimental immunotherapy, IMP761, continues to demonstrate a favorable safety profile, along with sustained suppression of T-cell activity, immune cells that are overly active in multiple sclerosis (MS) and other autoimmune diseases. These findings are based on data from healthy people enrolled in an ongoing first-in-human Phase 1…
People exposed to higher levels of certain manufactured compounds that persist in the environment are more likely to be diagnosed with multiple sclerosis (MS), a new study reports. A higher MS risk was associated with elevated levels of PFAS, also known as “forever chemicals,” and specific metabolites of PCBs,…
Fear of a sudden relapse or a gradual worsening of MS symptoms is common among people with multiple sclerosis (MS), according to a systematic review analyzing data from more than 3,000 people with MS. Those fears are not only widespread but also closely tied to poorer mental health, greater fatigue,…
Relapses in people with relapsing-remitting multiple sclerosis (MS) may be more common in spring and summer, coinciding with warmer temperatures, low humidity, and greater fluctuations in atmospheric pressure, according to a study from Poland. Stressful life events and infections were the most frequent potential relapse triggers, the study found.
In people with progressive multiple sclerosis (MS), treatment with the antioxidant lipoic acid did not improve walking or lessen other symptoms, such as fatigue, but it did show signs of slowing brain atrophy, or the loss of brain tissue. According to the researchers, this suggests possible positive biological…
An enzyme called CEMIP could be a target for small-molecule inhibitors that aim to promote myelin repair in people with multiple sclerosis (MS) and other conditions marked by myelin loss, a study found. Researchers discovered that CEMIP, which is elevated in areas of inflammatory nerve damage in people with…
Myelin, the protective coating that helps nerve signals travel quickly and efficiently, also plays a key role in the precise timing of communication between brain cells, a new study from scientists in the Netherlands shows. In a mouse model, the researchers found that the loss of myelin disrupted the coordination…
A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more tolerable for people with multiple sclerosis (MS) and other neurological conditions is enrolling participants at Clermont-Ferrand University Hospital in France. The study’s protocol was published in PLOS One, in a paper titled, “…
Eating more oily fish and wholegrain or wholemeal bread may help reduce a person’s risk of developing multiple sclerosis (MS), according to a new study that used data from a large U.K. database. The findings contribute to growing evidence showing that diet is “a potentially modifiable factor in MS…
Following negative Phase 3 trial results, Sanofi announced that it will not be pursuing approval of its experimental therapy tolebrutinib for primary progressive multiple sclerosis (PPMS). Meanwhile, a decision from the U.S. Food and Drug Administration (FDA) on tolebrutinib’s use in nonrelapsing secondary progressive MS (SPMS) is likely…
Children with multiple sclerosis (MS) who have more paramagnetic rim lesions (PRLs) — areas of chronic active inflammation seen on MRI scans — tend to lose more brain volume over time, a new study found. These lesions were common in pediatric MS, a rare form of the disease…
Specific disease-modifying therapies (DMTs) significantly slow the rate of brain volume loss in adults with multiple sclerosis (MS), a benefit that is directly linked to reduced long-term disability, according to a new review. A network meta-analysis of more than 26,000 patients confirms that therapies most effective at preserving…
A signaling molecule called erythropoietin (EPO) plays a key role in allowing the immune system to distinguish the body’s own cells from foreign threats, a study found. The findings could lead to new treatments for diseases like multiple sclerosis (MS), in which the immune system inadvertently starts to attack…
Gadoquatrane, a contrast agent Bayer is developing for MRI scans, showed similar safety and pharmacokinetic (PK) profiles — meaning how a drug moves into, through, and out of the body — in both children and adults. That’s according to data from the Phase 3 QUANTI Pediatric study (NCT05915026),…
Regular physical activity was independently linked to lower disability, fatigue, and depression over time in people with multiple sclerosis (MS), a new study found. Other lifestyle factors also supported better outcomes. For example, eating a higher-quality diet was independently associated with less disability, while not smoking was…